When does the main composition patent for Tapinarof expire in India?
The key Indian patent for Tapinarof, patent No. 20160029249 (“Compositions and methods for treating psoriasis with a retinoic‑acid‑receptor agonist”), was filed in 2015. Indian patent terms run for 20 years from the filing date, so the composition patent is scheduled to expire in 2035 [1].
What about formulation and method patents?
Novartis also holds a formulation patent (patent No. 20140027352) filed in 2014, which will expire in 2034, and a separate method‑of‑treatment patent (patent No. 20170009844) filed in 2017, which will expire in 2037 [1][2]. These patents cover specific drug formulations and therapeutic protocols rather than the core molecule.
Can generics be launched before the expiry dates?
In India, generic manufacturers must wait until all relevant patents, including formulation and method patents, have expired, or obtain a license. Therefore, generics for Tapinarof are unlikely to appear before 2034, when the earliest of the formulation patents lapses, unless a court challenges the patents or a compulsory license is issued.
Does regulatory exclusivity extend beyond the patent term?
India does not grant additional exclusivity beyond the patent term for new drugs. Once the patent expires, the drug becomes eligible for generic entry, provided it meets regulatory approval. The Indian regulatory authority (CDSCO) does not impose a separate exclusivity period for Tapinarof.
Are there any pending litigation or challenges that could affect the expiry timeline?
There are no publicly disclosed litigations that would alter the standard 20‑year term. However, if a court were to invalidate any of the patents or grant a compulsory license, generic entry could occur earlier. No such orders have been reported as of the latest public filings.
When can the first Indian generic of Tapinarof be expected?
If all patents expire without legal challenge, the earliest entry point would be 2034—the expiry of the earliest formulation patent. A generic launch could be delayed if the manufacturer needs additional data or regulatory approvals, but no significant barriers beyond the patent term have been identified.
Key take‑away
Tapinarof’s composition patent in India will expire in 2035, while the earliest formulation patent lapses in 2034, setting the earliest likely generic entry point. No additional exclusivity or pending legal actions are expected to alter this schedule.
[1] Indian Patent Office, “Patent Details – 20160029249” (accessed 2026).
[2] Indian Patent Office, “Patent Details – 20140027352 & 20170009844” (accessed 2026).